Author: Ravi Shankar

WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today announced the appointment of Scott M. Wasserman, MD, to the Company’s Board of Directors, effective October 19, 2026. Concurrent with Dr. Wasserman’s appointment, the Company also announced the resignation of Dennis Berman from the Company’s Board.

“We thank Dennis for his many contributions to the Company during his years of service,” said Amit Munshi, Chair of the Inhibikase Board of Directors.

Dr. Wasserman is currently the Chief Medical Officer of Kailera Therapeutics, a clinical-stage company developing GLP-1-based therapeutics for obesity and related conditions. Dr. Wasserman is a cardiologist with more than two decades of experience in clinical development and company leadership. At Amgen Inc., he served as Vice President, Global Development and Therapeutic Area Head for Bone, Cardiovascular, Metabolic and Neuroscience. He was Amgen’s first cardiologist and built the company’s cardiovascular and metabolic strategy, team and portfolio. He led the global development and approvals of Repatha (evolocumab), was instrumental in the development and U.S. FDA approval of Evenity (romosozumab) and oversaw the U.S. approval of Aimovig (erenumab).

“Scott has taken multiple programs from early development through global approval, and he has built clinical organizations at both large and emerging companies,” said Amit Munshi. “We look forward to benefiting from his expertise as we continue to advance our global Phase 3 IMPROVE-PAH study of IKT-001. We are pleased to welcome Scott to our Board.

“PAH is a progressive, life-threatening disease, and the pedigree of imatinib together with the recent preclinical and Phase 1 data for IKT-001 point to a very promising role for this asset in this difficult to treat condition,” said Dr. Wasserman. “This is an important time for Inhibikase, and I look forward to applying my experience in global clinical development and regulatory interactions as the Company advances IMPROVE-PAH.”

Scott brings deep expertise in clinical development to Inhibikase’s Board of Directors, spanning global development strategy, clinical trial design and execution, and global regulatory interactions. Most recently, Scott served as Venture Partner at Frazier Life Sciences, focusing on company creation. Prior to Frazier, Scott was the CEO and co-founder of Latigo Biotherapeutics, a venture-backed biotechnology company developing first and best-in-class, non-opioid pain medicines. Prior to his role with Latigo, Scott was Vice President, Global Development Therapeutic Area Head for Bone, Cardiovascular, Metabolic, and Neuroscience at Amgen. In addition to his role in the development of Repatha, Evenity, and Aimovig, Scott oversaw therapeutic development for a range of other conditions, including heart failure, anemia, obesity, and Alzheimer’s disease.

Prior to joining industry, Scott was on faculty at Stanford University in the Division of Cardiovascular Medicine conducting NIH-sponsored research on endothelial gene expression and served as a non-interventional cardiologist at the Veterans Administration Hospital in Palo Alto, CA. Scott received his BS, Magna Cum Laude from Haverford College and his MD, Magna Cum Laude from Harvard Medical School. He completed his postgraduate training in Internal Medicine and Cardiovascular Medicine at Stanford University and post-doctoral cardiovascular research at COR Therapeutics, Millennium Pharmaceuticals, and Stanford.

About Inhibikase (www.inhibikase.com) 

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit,” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.

Social Media Disclaimer

Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential of IKT-001, the advancement of the IMPROVE-PAH study, and the anticipated contribution of Dr. Wasserman to the Company’s board of directors. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts:
Investor Relations:
Michael Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com 

GRAND RAPIDS, Mich., Oct. 20, 2026 (GLOBE NEWSWIRE) — Independent Bank Corporation (NASDAQ: IBCP), the holding company for Independent Bank and Highpoint Community Bank, Michigan-based community banks, announced that today its Board of Directors declared a quarterly cash dividend on its common stock of $0.28 per share. This dividend is payable on November 13, 2026, to shareholders of record on November 3, 2026.

About Independent Bank Corporation

Independent Bank Corporation (NASDAQ: IBCP) is a Grand Rapids, Michigan-based bank holding company and the parent company of Independent Bank and, as of July 1, 2026, Highpoint Community Bank. Independent Bank Corporation has total assets of approximately $6.3 billion and operates from 66 locations across Michigan’s Lower Peninsula. Founded in 1864 as First National Bank of Ionia, Independent Bank provides a full range of financial services, including commercial banking, consumer banking, mortgage lending, and investment services. Independent Bank expects to complete the full system integration of Highpoint Community Bank’s operations on November 9, 2026. Until conversion, customers of Highpoint Community Bank should continue using their existing Highpoint Community Bank branches, checks, bank cards, online and mobile banking, and other banking services as usual.

For more information, please visit our Web site at: IndependentBank.com.

Contact:	William B. Kessel, President and CEO, 616.447.3933
	Gavin A. Mohr, Chief Financial Officer, 616.447.3929

Clinical conduct of both blarcamesine (ANAVEX®2-73) studies in healthy volunteers is now complete, data are expected to support clinical pharmacology characterization across pipeline programs

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system diseases with significant unmet medical needs, today provided a corporate update highlighting progress across its three core indications for blarcamesine (ANAVEX 2-73): early Alzheimer’s disease, Rett syndrome and Fragile X syndrome. Recent Company highlights include the completion of clinical conduct of the Drug-drug Interaction (DDI) and Absorption, Distribution, Metabolism and Excretion (ADME) studies of blarcamesine, clearance by the U.S. Food and Drug Administration (FDA) of the Company’s Investigational New Drug (IND) application in Fragile X syndrome, and an upcoming meeting with the FDA in November to discuss adding pediatric participants to the Phase 3 Rett syndrome study.

“Completion of the DDI and ADME studies represents an important milestone for blarcamesine, advancing the clinical pharmacology data package recommended by the FDA, which we expect to benefit our ongoing core programs.” said Terrie Kellmeyer, Ph.D., Interim Chief Executive Officer. “Together with the FDA’s recent clearance of our IND in Fragile X syndrome, these studies reflect positive progress and execution on timelines previously set forth. With these achievements, we believe that we are well positioned to continue to move forward on our strategic objectives through the remainder of the year.”

Alzheimer’s Disease Program

Anavex has completed clinical conduct of two clinical pharmacology studies of blarcamesine. The studies address clinical pharmacology data recommended by the FDA and the data are expected to support the Company’s FDA-focused development program. The FDA’s recommendation is aligned with feedback the Company received from the European Medicines Agency (EMA).

• DDI study: The last participant completed the study at the end of September, concluding clinical conduct.
  • The study was fully enrolled with 65 participants, all of whom received 30 mg of blarcamesine. Based on preliminary observations, no serious adverse events were reported. Full safety and pharmacokinetic data analysis is ongoing.
• ADME study: The last participant completed the study in mid-October, concluding clinical conduct.
  • The study enrolled 8 participants, all of whom received 30 mg of blarcamesine. Based on preliminary observations, no serious adverse events were reported. Full safety and pharmacokinetic data analysis is ongoing.
• Both studies enrolled healthy volunteers and were designed to further characterize blarcamesine’s clinical pharmacology profile. Their data are critical for the Alzheimer’s disease program and are also expected to support development in the Company’s Rett syndrome and Fragile X syndrome programs.

Rett Syndrome Program

• The Company has an FDA-aligned protocol for its Phase 3 study of blarcamesine in Rett syndrome in adult participants (ANAVEX2-73-RS-005). As previously announced on September 9, 2026, the FDA granted the Company a meeting to discuss adding pediatric participants to the Phase 3 protocol for November. Blarcamesine for the treatment of Rett syndrome has been granted Orphan Drug Designation by the FDA. The program remains on track with study start-up activities underway.

Fragile X Syndrome Program

• The Company submitted an (IND application for blarcamesine in Fragile X syndrome in September 2026, and, as previously announced on October 15, 2026, the FDA has cleared the IND. Blarcamesine for the treatment of Fragile X syndrome has been granted Orphan Drug Designation by the FDA. Study start-up activities are underway.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system diseases with high unmet medical need. Further information is available at www.anavex.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the Company’s clinical trial plans, preclinical and clinical data, clinical development programs and business prospects, blarcamesine’s potential, the Company’s expectations that the clinical conduct of the ADME and DDI clinical studies will support the Company’s FDA-focused development program, the Company’s plans to meet with the FDA in November to discuss adding pediatric participants to the Phase 3 protocol for blarcamesine in Rett syndrome, the impact of the FDA’s clearance of the Company’s IND application for Fragile X syndrome, are forward-looking statements. These statements can be identified by the use of forward-looking terminology, including the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could” and similar expressions, or the negative thereof. Many factors may cause actual results to differ materially from those projected in any of such forward-looking statements, including volatility in the Company’s stock price and the market in general; the Company’s ability to raise additional capital; challenges seeking, and ultimately obtaining, regulatory approval for the Company’s product candidates; the ability of Fast Track designation or breakthrough therapy designation to lead to a faster FDA review and approval process; the Company’s ability to maintain any benefits associated with Orphan Drug Designation, including market exclusivity; undesirable side effects caused by the Company’s product candidates; the Company’s ability to attract and retain highly qualified personnel; the Company’s reliance on third-parties; the Company’s ability to obtain and maintain sufficient intellectual property protection for our product candidates; the Company’s ability to defend against claims of intellectual property infringement; the Company’s ability to compete in the highly competitive biotechnology and pharmaceutical industries; and other the risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the Securities and Exchange Commission (“SEC”) on November 25, 2025, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2025, filed with the SEC on February 9, 2026, the Company’s Form 10-K/A for the fiscal year ended September 30, 2025, filed with the SEC on August 28, 2026, the Company’s Form 10-Q/A for the quarterly period ended December 31, 2025, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 28, 2026, and subsequent filings and furnishings with the SEC, which should be considered together with any forward-looking statement. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law.

Investor Relations:

SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com

Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com

Media:

Sam Brown, LLC
Christy Curran
Tel: 615-414-8668
Email: christycurran@sambrown.com

Milestone anniversary comes as SUMMIT surpasses 10 million guests in New York City and expands its immersive observatory experience globally

Photos of SUMMIT linked here, courtesy of SUMMIT One Vanderbilt

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) — Tomorrow SUMMIT One Vanderbilt, the world’s premier immersive observatory experience from SL Green Realty Corp. (NYSE: SLG), celebrates five years since opening on October 21, 2021. As the city’s top-performing observation attraction, SUMMIT’s fifth anniversary comes just one week after the observatory welcomed its 10 millionth visitor. The incredible milestones signify consistent growth as SUMMIT enters its next chapter, bringing its transformative art experience worldwide with the openings of SUMMIT in Paris in summer 2027 and Tokyo to follow.

Since opening in 2021, SUMMIT One Vanderbilt has redefined the traditional observation deck category by blending panoramic 360-degree views of New York City and state-of-the-art technology with multi-sensory artistic installations designed by renowned artist Kenzo Digital to create the most advanced, story-driven immersive experience. After opening at the end of a global pandemic, creating much-needed opportunities to reconnect with community, SUMMIT has become an integral part of the NYC skyline today, ingrained in the city’s history by playing host to local, national, and international cultural moments including the TCS New York City Marathon winners, a Fourth of July performance with Noah Kahan, the FIFA Women’s World Cup trophy, and more.

“Five years ago, we set out to create an experience that would offer an entirely new way to see New York City. Welcoming our 10 millionth visitor is a significant milestone, earned as guests from around the world continue to choose SUMMIT from everything this city has to offer,” said Marc Holliday, Chairman and Chief Executive Officer of SL Green Realty Corp. “As we celebrate five incredible years in New York, we’re grateful to the city and community that have embraced us from the beginning—and excited to bring the spirit of SUMMIT to Paris, Tokyo and other great cultural capitals around the world.”

To thank the city and the guests who have made five years possible, SUMMIT is taking its birthday celebration beyond One Vanderbilt and onto the streets of New York City. On October 21, 2026, a fleet of SUMMIT-branded taxis will fan out across Manhattan, surprising riders with free fares plus complimentary tickets to experience SUMMIT. Guests with tickets to visit that day can also enjoy special surprises including complimentary beverages from Après, free digital photo packages courtesy of Storibox, and additional giveaways across SUMMIT’s social channels. Learn more about fifth anniversary activations here.

In addition, the SUMMIT One Vanderbilt Foundation is marking five years of giving back in New York City and beyond. In recognition of the anniversary, the Foundation has committed five $25,000 donations to vital local and national nonprofit organizations selected for their alignment with its values: American Ballet Theatre, Garden of Dreams Foundation, Food1st, New York Cares, and Wounded Warrior Project.

The fifth anniversary arrives just one week after SUMMIT welcomed its 10 millionth visitor on October 14, 2026. To celebrate the moment, the lucky 10 millionth guest was surprised with an exclusive trip for two to Paris, France to be among the first to experience SUMMIT Paris, anticipated to open in summer 2027. Provided in partnership with United Airlines, the grand prize includes round-trip Polaris business class airfare and luxury accommodations at the Hotel Plaza Élysées. See photos and video HERE of the surprise moment, courtesy of SUMMIT One Vanderbilt.

As SUMMIT looks beyond its first five years, the brand is entering a new era of global growth through SUMMIT Entertainment Ventures (SEV), the joint venture between SL Green Realty Corp. and Kenzo Digital. SUMMIT Paris, crowning the top floors of Paris’ Triangle Building, will mark the first SUMMIT location outside of New York City when it debuts next year. Earlier this year, SEV also announced an agreement to bring SUMMIT to Tokyo, the second international location announced as part of its growing global portfolio, with additional destinations to come. International visitors can expect an evolution of the signature SUMMIT design made iconic in New York City customized to each new destination.

Over its first five years, SUMMIT One Vanderbilt has earned global recognition as the World Travel Awards’ Leading Tourist Attraction in North America in 2024, 2025, and 2026, along with recognition from the Tripadvisor Travelers’ Choice Awards, USA Today’s 10Best Immersive Art Experiences, Architizer’s A+ Awards, Fast Company’s Innovation by Design Awards, ELLE Magazine’s “Most Instagrammable Place in the World” and Tiqets’ Most Innovative Venue in the U.S.

Tickets to experience SUMMIT One Vanderbilt are available at summitov.com. Media kit with photos and videos of SUMMIT One Vanderbilt is linked here.

About SUMMIT One Vanderbilt
Since opening in 2021, SUMMIT One Vanderbilt has become the world’s most immersive observatory experience, welcoming over 10 million guests from around the globe. Combining unparalleled 360-degree views of New York City and beyond, multi-sensory artistic experiences created by Kenzo Digital, and cutting-edge technology, SUMMIT offers an unprecedented guest experience spanning art, design, and sensory adventure from the highest accessible viewpoint in Midtown Manhattan. With plans underway to expand the SUMMIT experience internationally, including forthcoming locations in Paris and Tokyo alongside other global destinations, the brand continues to redefine immersive entertainment and observation experiences worldwide.

The 65,000 square-foot entertainment space features equally contemplative and thrilling experiences across three floors, world-class food and cocktails from the Après bar and café, an outdoor terrace, a thoughtfully curated boutique, and Ascent, the world’s largest outdoor glass elevator.

summitov.com
@SUMMITOV

About SL Green Realty Corp.
SL Green Realty Corp., Manhattan’s largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing the value of Manhattan commercial properties. As of June 30, 2026, SL Green held interests in 54 buildings totaling 30.6 million square feet, which included ownership interests in 29.2 million square feet and 1.4 million square feet securing debt and preferred equity investments, excluding fund investments, and managed 4 buildings totaling 0.9 million square feet owned by third parties.

PRESS CONTACT
summit@berlinrosen.com

Quanzhou, China, Oct. 20, 2026 (GLOBE NEWSWIRE) — INLIF LIMITED (Nasdaq: INLF) (together with all its subsidiaries and consolidated entities, the “Company” or “INLIF”), a company engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms, today announced the closing of its previously announced registered direct offering conducted on a best-efforts basis.

The Company issued an aggregate of 435,000 Class A Ordinary Shares, par value of US$0.0001 per share, of the Company (the “Ordinary Shares”), pre-funded warrants to purchase up to 1,908,750 Ordinary Shares (the “Pre-Funded Warrants”), Series A warrants to initially purchase up to 2,343,750 Ordinary Shares (the “Series A Warrants”), Series B warrants to initially purchase up to 2,343,750 units (the “Series B Warrants”, each unit consisting of one Ordinary Share, or one Pre-Funded Warrant in lieu thereof and one Series A Warrant), and Series C warrants to purchase a number of Ordinary Shares to be determined in accordance with their terms (the “Series C Warrants” and, together with the Series A Warrants and the Series B Warrants, the “Ordinary Warrants”), in a registered direct offering (the “Offering”). Each Ordinary Share or Pre-Funded Warrant was sold together with one accompanying Series A Warrant, one accompanying Series B Warrant and one accompanying Series C Warrant at a combined purchase price of US$1.60 per Ordinary Share and accompanying Ordinary Warrants, or US$1.5999 per Pre-Funded Warrant and accompanying Ordinary Warrants, which equals the combined purchase price per Ordinary Share and accompanying Ordinary Warrants minus US$0.0001, the exercise price of each Pre-Funded Warrant.

The Series A Warrants are immediately exercisable at US$1.60 per Ordinary Share and will expire five years after closing. The Series B Warrants are immediately exercisable at US$1.60 per unit and will expire 60 days after issuance. Each of the Series A Warrants and Series B Warrants is subject to a one-time downward exercise price reset on the twentieth trading day after closing along with other adjustments therein. The Series C Warrants will be exercisable at US$0.0001 per share for additional Ordinary Shares determined by a price-based adjustment over the first ten trading days beginning on issuance.

The Company received total gross proceeds of approximately US$3.75 million, prior to deducting placement agent fees, legal fees, administrative and other offering-related expenses. The Company intends to use the net proceeds from the Offering for the Company’s directors and officers and for working capital purposes, including the Phase II manufacturing facility, production and R&D equipment, its Xiamen headquarters and R&D platform, new product R&D (including industrial robots), talent recruitment, and working capital, with deployment expected over the next one to two years.

Maxim Group LLC acted as the sole placement agent for the Offering. Ortoli Rosenstadt LLP acted as U.S. securities counsel to the Company, and Pryor Cashman LLP acted as U.S. securities counsel to the placement agent, in connection with the Offering.

The Offering was made pursuant to the Company’s “shelf” registration statement on Form F-3 (File No. 333-292580), initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 5, 2026 and declared effective on January 12, 2026. A final prospectus supplement and accompanying prospectus describing the terms of the Offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov.

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. No offering, sale or solicitation shall be permitted in any jurisdiction where such offering or sale would be unlawful prior to registration, exemption or qualification under the local securities laws of such jurisdiction.

About INLIF LIMITED

INLIF is a holding company and an exempted company incorporated in the Cayman Islands with limited liability. Through its operating entity in the People’s Republic of China, Ewatt Robot Equipment Co. Ltd., established in September 2016, INLIF is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. It is also a provider of installation services and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. The Company produces an extensive portfolio of injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms, all developed by itself. It has also built experience in industrial automation solutions, including in the new energy sector, as well as intelligent robotics in recent years. For more information, please visit the Company’s website: https://ir.yiwate88.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions, and includes such statements regarding timing of closing, satisfaction of closing conditions, and expected proceeds from the offering. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. 

These forward-looking statements are subject to substantial risks and uncertainties that may cause actual results, performance or achievements to differ materially from those expressed or implied, including without limitation: the Company’s ability to complete the Offering in accordance with the expected timeline and terms; satisfaction of closing conditions; the planned use and actual deployment of net proceeds; adverse changes in global market conditions and capital market sentiment; risks relating to the Company’s business strategy adjustment and asset optimization;  the ability to maintain the Company’s Nasdaq listing status; changes in industry policies and regulatory rules; future capital financing needs; and other risk factors disclosed in the Company’s periodic filings and subsequent submissions with the SEC, including its Annual Report on Form 20-F. 

Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission.

Contact

INLIF LIMITED
Investor Relations Department
Email: ir@yiwate88.com

BOCA RATON, Fla., Oct. 20, 2026 (GLOBE NEWSWIRE) — ADT Inc. (NYSE: ADT) will release its third quarter 2026 financial results before the market opens on Tuesday, November 3, 2026. Following the release, management will host a conference call at 10 a.m. ET to discuss these financial results and conduct a question-and-answer session.

Participants may listen to a live webcast through the investor relations website at investor.adt.com. Alternatively, participants may listen to the live call by dialing 1-833-461-5787 (toll-free) or 1-585-542-9983 and providing the access code 472959920. A replay of the webcast will be available on the website within 24 hours after the event.

About ADT 

ADT is a leading provider of security, interactive, and smart home solutions serving residential and small business customers in the U.S. Through innovative offerings, unrivaled safety, and a premium customer experience delivered by the largest network of smart home security professionals in the U.S., ADT empowers people to protect and connect to what matters most, every second, every day. For more information, visit ADT.com.

Investor Relations:
investorrelations@adt.com
                        
Media Relations:
media@adt.com

Five-year, $125,000 commitment will support the next generation of researchers advancing military and public safety family health

OTTAWA, Ontario, Oct. 20, 2026 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX: CGY), a mission-critical solutions company focused on defence, space, healthcare and other strategic critical infrastructure sectors, today announced a five-year, $125,000 commitment in partnership with the Canadian Institute for Military and Veteran Health Research (CIMVHR) to establish the Calian-Nicola T. Fear Memorial Military and Public Safety Family Health Research Scholarship, in honour of the late Professor Nicola Fear CBE. Announced at the CIMVHR Forum 2026 in Halifax, the scholarship will provide an annual award of $25,000 for five years to support Masters and Doctoral research graduate students.

Professor Fear was an internationally respected leader in military health research and a Professor of Military Epidemiology and Director of the King’s Centre for Military Health Research at King’s College London. In 2025, she was recognized as the first international CIMVHR Fellow and dedicated her career to understanding the impact of military service on personnel, Veterans, and their families and building international collaboration in military health research.

Reflecting that legacy, preference for the scholarship will be given to projects that contribute practical, evidence-based insights that can improve the health and wellness of military and public safety families.

“Military and public safety families make an extraordinary contribution alongside those who serve, and they face distinct health and well-being needs that deserve dedicated research and attention,” said Lindsay Williams, Vice President, Health Services, Calian. “Through this scholarship we want to invest in the next generation of researchers and help turn evidence into better care, stronger programs and better outcomes for military and public safety families. It is also fitting way to honour Professor Fear and the tremendous contributions she made to this field.”

“Calian’s commitment to establishing this scholarship creates an important opportunity for researchers to build on Nicola’s legacy and to ensure her influence remains a lasting part of this community,” said Dr. Nicholas Held, Scientific Director of CIMVHR. “It’s a meaningful way to celebrate the future discoveries, partnerships, and advancements that will grow from the foundation she helped build.”

Calian has a long history of supporting members of the Canadian Armed Forces and Public Safety members, Veterans and families through the delivery of healthcare, training and other mission-critical solutions. The company is participating as a Sponsor at CIMVHR Forum 2026, taking place October 19 to 21 in Halifax. The Forum brings together researchers, healthcare professionals, military, public safety, government stakeholders and community partners to advance military, public safety and family health and well-being.

This investment supports Calian’s commitments under the Government of Canada’s Industrial and Technological Benefits (ITB) Policy, which encourages investments that strengthen Canadian innovation, research, skills and economic capacity.
  
About Calian
www.calian.com
For over 40 years, Calian has delivered mission-critical solutions when failure is not an option. Trusted worldwide, we empower organizations in critical industries to overcome obstacles, manage risks and drive progress. By combining the expertise of our people, proven industry insight, cutting-edge technology, bold innovation, and global reach, we deliver tailored solutions that solve complex challenges. Headquartered in Ottawa, Canada, with over 6,000 people around the world, Calian’s solutions protect lives, strengthen security, foster global connectivity and drive economic progress, making a lasting impact where and when it matters most.

Product or service names mentioned herein may be the trademarks of their respective owners.

Media inquiries:
media@calian.com
613-599-8600
Investor Relations inquiries:
ir@calian.com

About CIMVHR
The Canadian Institute for Military and Veteran Health Research (CIMVHR) acts as a national convenor between academia, government, industry and the not for-profit-sector to improve the health of military, Veterans, and families by facilitating new research, increasing research capacity, and effective knowledge mobilization. With a network of academic researchers from across Canada, it serves as the hub for over 50 Canadian universities and colleges who have agreed to work together to improve the health of these populations. To learn more visit www.cimvhr.ca
CIMVHR: Serving those who serve us.

DISCLAIMER 
Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events. Such statements are generally accompanied by words such as “intend”, “anticipate”, “believe”, “estimate”, “expect” or similar statements. Factors which could cause results or events to differ from current expectations include, among other things: the impact of price competition; scarce number of qualified professionals; the impact of rapid technological and market change; loss of business or credit risk with major customers; technical risks on fixed price projects; general industry and market conditions and growth rates; international growth and global economic conditions, and including currency exchange rate fluctuations; and the impact of consolidations in the business services industry. For additional information with respect to certain of these and other factors, please see the Company’s most recent annual report and other reports filed by Calian with the Ontario Securities Commission. Calian disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance can be given that actual results, performance or achievement expressed in, or implied by, forward-looking statements within this disclosure will occur, or if they do, that any benefits may be derived from them. 

Calian · Head Office · 770 Palladium Drive · Ottawa · Ontario · Canada · K2V 1C8 
Tel: 613.599.8600 · Fax: 613-592-3664 · General info email: info@calian.com

SINGAPORE, Oct. 20, 2026 (GLOBE NEWSWIRE) — ChowChow Cloud International Holdings Limited (“Chowchow”, the “Company”) (NYSE American: CHOW) announced today that the Company had become aware of unusual trading activity in its ordinary shares on the NYSE American LLC (the “NYSE American”) on October 19, 2026. The Company is issuing this press release pursuant to Section 401(d) of the NYSE American Company Guide. The Company has made inquiries and has been unable to determine whether corrective actions are appropriate at this time. The Company is further announcing that there has been no material development in its business and affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action.

About ChowChow Cloud International Holdings Limited

ChowChow Cloud is a pioneer in providing one-stop cloud solutions that support companies across the IT industry value chain throughout their entire cloud transformation journey from consulting, deployment and migration to cloud environment building and management. ChowChow Cloud was founded in December 2014 by a group of passionate and experienced professionals, who envisioned the potential of cloud technology to transform the way businesses of various sizes operate. Recognizing the growing need for digitization and the benefits that cloud technology could bring to businesses, ChowChow Cloud’s founders set out to create a company that would bridge the gap between cloud services providers and companies who seek to move to the cloud.

Forward-looking Statements

This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements give our current expectations, opinion, belief or forecasts of future events and performance. A statement identified by the use of forward-looking words including “will,” “may,” “expects,” “projects,” “anticipates,” “plans,” “believes,” “estimate,” “should,” and certain of the other foregoing statements may be deemed forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company undertakes no obligation to update any such forward-looking statements after the date hereof to conform to actual results or changes in expectations, except as required by law.

For more information, please contact:

Investor Relations Team
ChowChow Cloud International Holdings Limited
Email: ir@chochowcloud.com

ORION CORPORATION
STOCK EXCHANGE RELEASE – INSIDE INFORMATION
20 OCTOBER 2026 at 20.20 EEST
        

Inside information: Orion upgrades full-year outlook for 2026

Orion Corporation upgrades the full-year outlook for 2026 both for the part regarding net sales and operating profit. Orion’s royalty income has increased faster than expected during the first nine months of 2026, and this good development is anticipated to continue during the remainder of the year. Due to this reason, Orion upgrades the full-year outlook for 2026.

New full-year outlook for 2026, provided on 20 October 2026

Net sales are estimated to be EUR 2,070 million to EUR 2,140 million.

Operating profit is estimated to be EUR 730 million to EUR 790 million.

Previous full-year outlook for 2026, provided on 17 July 2026

Net sales are estimated to be EUR 2,000 million to EUR 2,100 million.

Operating profit is estimated to be EUR 650 million to EUR 750 million.

Orion will publish its Interim Report for January-September 2026 on Wednesday, 28 October 2026 at approximately 12.00 noon EET.

Orion Corporation

Liisa Hurme President and CEO

Mikko Kemppainen General Counsel

Contact person:
Tuukka Hirvonen, Head of Investor Relations

tel. +358 10 426 2721

                                                 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com

Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.

Distinguished leaders to affix commemorative plaque to the first-of-class vessel, highlighting Louisiana’s critical role in advancing U.S. naval unmanned maritime operations.

NEW IBERIA, La., Oct. 20, 2026 (GLOBE NEWSWIRE) —

WHAT: HII (NYSE: HII), America’s largest shipbuilder and global leader in autonomous maritime systems, will host a celebration and hull plaque dedication ceremony for the first-in-class ROMULUS 151 unmanned surface vessel (USV) celebrating the production of ROMULUS 151 unmanned surface vessels (USV) for the U.S. Navy.

The event, Tuesday, Oct. 27, 2026, will include remarks from Louisiana Governor Jeff Landry, HII President and CEO Chris Kastner and President of Breaux Brothers Enterprise, Brannon Breaux.

The program will feature the ceremonial installation of a commemorative hull plaque on the first-in-class ROMULUS 151 vessel.

The U.S. Navy’s recently award HII a contract to build 10 ROMULUS vessels under the Medium Unmanned Surface Vessel (MUSV) program, reinforcing the importance of the Louisiana and Gulf Coast maritime industrial base in delivering advanced defense capabilities, sustaining skilled shipbuilding jobs and strengthening national security.

Media are invited to attend and will have opportunities for photos, video and interviews.

A classic Cajun lunch will follow the program.

NOTE: This event is not open to the public.

WHERE:

Breaux Brothers Enterprises
5816 Daspit Road
New Iberia, LA 70563

WHEN:

Tuesday, Oct. 27, 2026
10 a.m. – 12 p.m.
Media should arrive by 9:45 a.m.  

RSVP:

Media interested in attending should RSVP gregory.j.mccarthy@hii-co.com by noon on Friday, Oct. 23.

PARKING & CHECK‑IN:

Media parking will be available in a designated area near the main entrance.

Signage and staff will direct arriving media to the check‑in area, where credentials will be verified before escorted entry to the event site.

About HII

HII is America’s Seapower Company. The nation’s largest shipbuilder, HII builds the manned and unmanned maritime systems and all-domain mission technologies that project U.S. and allied power around the world. With a more than 140-year history of advancing U.S. national security, HII is headquartered in Virginia and employs 45,000 people across three divisions. For more information, visit:

• HII on the web: https://www.HII.com/
• HII on Facebook: https://www.facebook.com/TeamHII
• HII on X: https://www.twitter.com/WeAreHII
• HII on Instagram: https://www.instagram.com/WeAreHII
• HII on LinkedIn: https://www.linkedin.com/company/wearehii

Contact:
Greg McCarthy
(202) 264-7126
gregory.j.mccarthy@hii-co.com